New treatment options for metastatic renal cell carcinoma

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Hutson, Thomas E.
• dc.contributor.author Bellmunt Molins, Joaquim, 1959-
• dc.contributor.author Strijbos, Michiel H.
• dc.contributor.author Rodriguez-Vida, Alejo
• dc.date.accessioned 2018-05-18T07:31:44Z
• dc.date.available 2018-05-18T07:31:44Z
• dc.date.issued 2017
• dc.description.abstract During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axitinib) or the mammalian target of rapamycin pathway (temsirolimus, everolimus) were since then progressively approved for first-line or later-line use in the treatment of patients with advanced RCC and became the new standard of care. As a result, the survival of patients with advanced RCC has significantly improved from a median overall survival of approximately 12 months in the cytokines era to more than 26 months with first-line VEGF inhibitors. During the two last years, the treatment of advanced RCC has witnessed a second revolution with the advent of immune checkpoint inhibitors, especially agents targeting the programmed cell death-1 receptor, as well as with the advent of new generation tyrosine-kinase receptor inhibitors. This article will review the new therapeutic options available for the treatment of advanced RCC, as well as the future potential molecular targets that are currently being investigated.
• dc.format.mimetype application/pdf
• dc.identifier.citation Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH. New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017 May 9;2(2):e000185. DOI: 10.1136/esmoopen-2017-000185
• dc.identifier.doi http://dx.doi.org/10.1136/esmoopen-2017-000185
• dc.identifier.issn 2059-7029
• dc.identifier.uri http://hdl.handle.net/10230/34682
• dc.language.iso eng
• dc.publisher BMJ Publishing Groupca
• dc.relation.ispartof ESMO Open. 2017 May 9;2(2):e000185
• dc.rights This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword Renal cell carcinoma
• dc.subject.keyword New treatments
• dc.subject.keyword Tyrosine-kinase inhibitor
• dc.subject.keyword Immunotherapy
• dc.subject.keyword Programmed cell death-1
• dc.subject.other Ronyons -- Càncer -- Tractament
• dc.title New treatment options for metastatic renal cell carcinomaca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion